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Abstract 1 
A range of Chlamydiales species have previously been detected in a variety of 2 
Australian marsupials, including koalas and western barred bandicoots. Thirty-3 
nine ocular, urogenital or nasal swabs were obtained from 37 wild western 4 
barred bandicoots. Chlamydia culture and antibiotic susceptibility testing were 5 
performed in cycloheximide treated HEp-2 cells in 96 well microtiter plates. 6 
Chlamydia spp were isolated from 11 specimens from 9 (24.3%) bandicoots. 7 
All isolates were identified as Chlamydiales by Chlamydiales specific 16S and 8 
23S rRNA primers using conventional polymerase chain reaction (PCR) and 9 
confirmed to be Chlamydia pneumoniae by a C. pneumoniae specific ompA 10 
based real-time PCR assay and 16S rRNA and 23S rRNA signature sequence 11 
analyses. The MICs of azithromycin, doxycycline, ciprofloxacin and 12 
enrofloxacin of 10 C. pneumoniae isolates from these bandicoots ranged from 13 
0.015-1 μg/ml, 0.25-1 μg/ml, 0.25-2 μg/ml and 0.25-0.5 μg/ml respectively. 14 
The MIC90 and minimal bactericidal concentrations (MBC) were within the 15 








The range of hosts infected by Chlamydiales has been expanding. Recent 2 
studies using a combination of molecular methods and cell culture have 3 
identified several existing and some novel Chlamydiales species infecting a 4 
wide range of Australian marsupials including koalas and western barred 5 
bandicoots (3). Formerly found over much of Western Australia, western 6 
barred bandicoots (Perameles bougainville) are now an endangered species 7 
found in the wild only on Bernier and Dorre Islands off the coast of Western 8 
Australia (8). Detection of chlamydial organisms including Chlamydia 9 
pecorum and unidentified Chlamydiales in these animals has previously been 10 
associated with clinical diseases in the form of conjunctivitis, lid proliferation, 11 
corneal opacity as well as an asymptomatic state (16). The in vitro 12 
susceptibilities of Chlamydia spp isolated from Australian marsupials, 13 
including bandicoots, have not been reported. The purpose of this study was to 14 
isolate chlamydia species in tissue culture from specimens obtained from these 15 
unique hosts and to determine the growth characteristics, species and in vitro 16 
antibiotic susceptibilities.      17 
                                                                                                                                                                  18 
Methods 19 
Specimen collection. Ocular, urogenital or nasal swabs were obtained from 20 
western barred bandicoots from Dryandra, Western Australia (WA) and 21 
 3
Bernier Islands, WA. All animals sampled were from wild populations. 1 
Thirteen of these animals showed clinical signs of disease in the form of 2 
conjunctivitis, proliferation of the eyelid and possible pneumonia. Five were 3 
noted to have cataracts or corneal scarring suggestive of previous ocular 4 
disease.  5 
Cell culture. Isolation of chlamydia spp. was performed in cycloheximide-6 
treated HEp-2 cells grown in 96-well microtiter plates as previously described 7 
(14). Culture confirmation was done by staining with a chlamydia genus 8 
specific fluorescein-conjugated monoclonal antibody (Pathfinder Chlamydia 9 
Confirmation System, Kallestad Diagnostics, Chaska, MN). Each specimen 10 
was passaged up to 6 times. Isolates that were positive by culture were 11 
propagated for further characterization including susceptibility testing and 12 
molecular diagnostic studies.  13 
In vitro susceptibility testing.  Susceptibility testing was performed in cell 14 
culture using HEp-2 cells as previously described (10). Azithromycin (Pfizer 15 
Central Research, Groton, CT), ciprofloxacin (Miles Pharmaceuticals, West 16 
Haven, CT), enrofloxacin (Bayer Corp., Shawnee Mission, KS) and 17 
doxycycline were supplied as powders and solubilized according to the 18 
manufacturers’ instructions. Each well was inoculated with 0.1 ml of the test 19 
isolate diluted to yield 103 to 104 inclusion-forming units per ml, centrifuged 20 
at 900 × g for 1 hour, and then incubated at 35°C for 1 hour. Wells were then 21 
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aspirated and overlaid with 0.2 ml of overlay medium containing 1 μg/mL of 1 
cycloheximide and serial twofold dilutions of the test drug. After incubation at 2 
35°C for 72 hours, cultures were fixed and stained for inclusions with 3 
fluorescein-conjugated antibody to the lipopolysaccharide genus antigen. The 4 
minimum inhibitory concentration (MIC) was the lowest antibiotic 5 
concentration at which no inclusions were seen. The minimal bactericidal 6 
concentration (MBC) was determined by aspirating the antibiotic-containing 7 
medium, washing wells twice with phosphate-buffered saline and adding 8 
antibiotic-free medium. Cultures were frozen at 70°C, thawed, passed onto 9 
new cells and incubated for 72 hours and then fixed and stained as described 10 
above. The MBC was considered to be the lowest antibiotic concentration, 11 
which resulted in no inclusions after passage. All tests were run in triplicate.   12 
DNA extraction. DNA from culture positive isolates was extracted using the 13 
DNeasy tissue kit (Qiagen, Valencia, CA), as per manufacturer’s instructions 14 
and stored at -20°C prior to PCR analysis.  15 
C. pneumoniae species identification 16 
1. 16S and 23S rRNA genes signature sequencing. Amplification/sequencing 17 
primers used for 16S rRNA gene and 23S rRNA gene products were 16SIGF 18 
5’-CGGCGTGGATGAGGCAT-3’, 16SIGR 5’- TCAGTCCCAGTGTTGGC-19 
3’, U23F 5’-GATGCCTTGGCATTGATAGGC GATGAAGGA-3’ and 20 
23SIGR 5’-TGGCTCATCATGCAAAAGGCA-3’, as described by Everett et 21 
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al (7). PCR was performed using Qiagen ProofStart DNA polymerase kit, at 1 
95oC x 5 min, then 45 cycles of 94oC x 30 sec, 60oC x 30 sec, 72oC x 60 sec, 2 
with a final extension for 5 min at 72oC. PCR products were purified with 3 
Qiagen QIAquick PCR Purification kit and sequenced in both directions 4 
(GeneWiz, North Brunswick, NJ). 5 
2.  C. pneumoniae specific real-time PCR TaqMan assay. The C. 6 
pneumoniae specific primers and probe targeting a 85 bp highly conserved and 7 
specific region of the ompA gene were as follows: QMOMP1 5’-GATCCGC 8 
TGCTGCAAACTATACT-3’, QMOMP2 5’-9 
GTGAACCACTCTGCATCGTGTAA-3’, probe QMOMPS 5’- FAM-10 
TAGGCCGGGTTAGGTCTATCTACGGCAGT-TAMRA-3’ (1). Real-time 11 
PCR was performed using the Roche LightCycler version 2.0, at 95oC x 10 12 
min, then 45 cycles of 95oC x 5 sec, 65oC or 60oC x 10 sec, 72oC x 10 sec. A 13 
low titer TW-183 isolate of C. pneumoniae (ATCC VR-2282) was used as a 14 
positive control and double distilled water was used as a negative control in all 15 
the in vitro experiments, PCRs and sequencing reactions. 16 
Sequence analysis.  The sequences were analyzed using BLAST 2 17 
[http://www.ncbi.nlm. nih.gov/blast/bl2seq/ bl2.html] and compared to the 18 
Chlamydiales sequences of 16S rRNA and 23S rRNA available in GenBank, 19 




Culture. Thirty-nine ocular, throat, and cloacal specimens were obtained from 2 
37 bandicoots. A total of 11 (28.2%) specimens from 9 (24.3%) bandicoots 3 
were positive for chlamydia spp after 3-6 passages. Inclusions varied in size 4 
and granularity, but were very similar in appearance to those of human 5 
isolates. Of the 11 positive swabs, 4 were obtained from the left eye, 2 from 6 
the right eye, 1 from the nose and 3 from the throat. Source site of one swab 7 
was not clear from the label. 8 
16S and 23S rRNA gene based PCR. PCR was performed on 10 of the 11 9 
culture positive specimens. All 10 specimens were shown to belong to 10 
Chlamydiales by Chlamydiales specific 16S and 23S rRNA primers. 11 
OmpA based real time PCR. All 10 isolates tested positive by C. pneumoniae 12 
specific ompA based PCR assay. 13 
Sequence analysis. Sequence analysis of 16S and 23S rRNA genes signature 14 
regions revealed that all 10 bandicoot isolates were identical to each other. 15 
The signature sequences of the 16S rRNA and 23S rRNA genes from bandicoot 16 
C. pneumoniae are currently available in GenBank, accession numbers 17 
DQ444323 and DQ465990, respectively.  As shown in Table 2, BLAST 18 
analysis of the 551 bp segment of 23S rRNA gene signature sequence 19 
demonstrated that bandicoot isolates were 99.6 % and 99.1 % identical to 20 
human (2 bp difference) and equine biovar (5 bp) of C. pneumoniae, 21 
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respectively. BLAST analysis of the 294 bp 16S rRNA gene signature segment 1 
showed that bandicoot isolates were 99.3% identical to human biovar (2 bp 2 
variation), 99.5% to koala biovar (1 bp) and 98.9% to equine biovar (3 bp).  3 
In vitro susceptibility testing. The MIC50, MIC90 and MBC90 values for 4 
bandicoot isolates of C. pneumoniae are shown in Table 1. The range of MICs 5 
and MBCs for azithromycin was 0.015-1 µg/ml, doxycycline 0.25-1 µg/ml, 6 
ciprofloxacin 0.25-2 µg/ml and enrofloxacin 0.25-0.5 µg/ml.  7 
 8 
Discussion 9 
We were able to isolate chlamydia spp in tissue culture from multiple 10 
anatomic sites from 24% bandicoots in this sample. Tissue culture using 11 
cycloheximide-treated HEp-2 cells appears to be an effective system for 12 
isolation and propagation of these organisms. The isolates were propagated for 13 
further analysis by PCR.  All isolates were confirmed to be Chlamydiales by 14 
staining with Chlamydiaceae specific monoclonal antibodies in cell culture, 15 
Chlamydiales specific 16S rRNA and 23S rRNA PCR and subsequently 16 
identified as C. pneumoniae by a highly species-specific ompA based real time 17 
PCR assay using specific primers and a specific probe. In addition, 16S rRNA 18 
and 23S rRNA signature sequence analysis revealed a similarity of 99.3% and 19 
99.6 % respectively to human isolates of C. pneumoniae; similarity more than 20 
95% is enough to confirm the species (7). C. pneumoniae is considered to be a 21 
 8
primarily human respiratory pathogen although recent reports have identified 1 
koalas, frogs (2, 11, 12) and horses (15) as additional hosts. Furthermore, the 2 
koala biovar, which has previously been isolated from koalas and frogs, was 3 
recently identified in human carotid plaque specimens obtained from patients 4 
undergoing elective endarterectomy for carotid artery disease in Australia (6). 5 
The identification of C. pneumoniae infections in bandicoots provides further 6 
evidence for the expanding diversity of this species. The identification of an 7 
increasing number of hosts and novel biovars of C. pneumoniae raises some 8 
interesting questions about the evolution and epidemiology of this pathogen, 9 
specifically the presence of animal reservoirs and additional modes and or 10 
directions of transmission across species. Additional studies are needed to gain 11 
further understanding of these issues. 12 
Although molecular techniques have been increasingly used in the past few 13 
years for detection of Chlamydiales sequences in a wide range of animal and 14 
environmental sources, and in combination with sequencing have facilitated 15 
discovery of novel Chlamydiales (3) and an increasing range of chlamydial 16 
hosts, isolation and propagation of the organism in culture allows further 17 
antigenic and molecular characterization of isolates and remains essential for 18 
determination of in vitro susceptibilities. Several of the animals in this study 19 
were initially treated with beta-lactam antibiotics without response but 20 
subsequently responded to intramuscular tetracycline. In vitro susceptibility 21 
 9
testing of these C. pneumoniae isolates to azithromycin, ciprofloxacin and 1 
doxycycline demonstrated antibiotic susceptibilities similar to those reported 2 
for human isolates (9). Enrofloxacin, a veterinary quinolone, has been 3 
demonstrated to be very active in vitro against C. psittaci (5) and has been 4 
used for treatment and prevention of psittacosis in birds (13). Enrofloxacin has 5 
not been tested against C. pneumoniae. Although in vitro susceptibilities may 6 
not necessarily predict in vivo efficacy, these data indicate a possible role for 7 
this drug in the treatment of C. pneumoniae infections in Australian 8 
marsupials.  9 
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Table 1. In vitro antibiotic susceptibilities of 11 bandicoot isolates of C. 1 
pneumoniae 2 
 3 
Drug MIC (mg/l)+      MBC (mg/l)+    
 Range 50%  90%  Range  90%  
Azithromycin 0.015-1  0.5  1  0.015-1  1  
Doxycycline 0.25-1  0.25  1  0.25-1  1  
Ciprofloxacin 0.25-2  0.5  2  0.25-2  2  
Enrofloxacin 0.25-0.5  0.5  0.5  0.25-0.5  0.5  













Table 2. Signature sequence similarities of Western Barred Bandicoot C. 1 
pneumoniae isolates to existing C. pneumoniae biovars  2 
Chlamydia pneumoniae  16S rRNA (294 bp)  23S rRNA (551 bp)  
Human biovar  99.3 (2 bp)*  99.6(2 bp)  
Koala biovar  99.5 (1 bp)  Not available  
Equine biovar  98.9 (3 bp)  99.1 (5 bp)  
Other Chlamydia species  ≤94.5% (≥16 bp)  ≤94.7 (≥29 bp)  
















Photomicrograph of a bandicoot C. pneumoniae isolate showing characteristic chlamydial 
inclusions in Hep-2 cell culture under 200x magnification 
Chlamydial 
inclusions 
